Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $22.60 Consensus Price Target from Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $22.60.

A number of research firms have recently commented on AARD. Oppenheimer dropped their price target on Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Stifel Nicolaus reiterated a “hold” rating and set a $6.00 price objective (down from $24.00) on shares of Aardvark Therapeutics in a report on Monday, March 2nd. B. Riley Financial initiated coverage on Aardvark Therapeutics in a report on Wednesday, January 28th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings downgraded Aardvark Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $47.00 price objective on shares of Aardvark Therapeutics in a report on Monday, January 12th.

Aardvark Therapeutics Price Performance

NASDAQ AARD opened at $5.46 on Friday. The firm has a market cap of $119.14 million, a P/E ratio of -1.86 and a beta of 5.13. The stock’s 50-day moving average is $5.72 and its 200-day moving average is $10.18. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.81) EPS for the quarter, hitting analysts’ consensus estimates of ($0.81). Equities analysts anticipate that Aardvark Therapeutics will post -3.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AARD. SymBiosis Capital Partners LLC bought a new position in shares of Aardvark Therapeutics during the fourth quarter worth about $6,255,000. Millennium Management LLC bought a new position in shares of Aardvark Therapeutics during the third quarter worth about $4,248,000. Cresset Asset Management LLC bought a new position in shares of Aardvark Therapeutics during the third quarter worth about $1,951,000. Geode Capital Management LLC grew its holdings in shares of Aardvark Therapeutics by 53.5% during the fourth quarter. Geode Capital Management LLC now owns 297,865 shares of the company’s stock worth $3,910,000 after buying an additional 103,830 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock worth $7,386,000 after buying an additional 94,744 shares in the last quarter.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.